Revenio Group (REG1V) investor relations material

Deal rationale and strategic fit

• Creates a leading turnkey solutions provider in global eye care, expanding product, software, and customer portfolios with limited overlap.

• Expands accessible market from EUR 1 billion to EUR 2.5 billion, entering fast-growing OCT and multimodal device segments.

• Strengthens position across optical retail, optometry, and ophthalmology, leveraging both companies' innovation and commercial reach.

• Combines complementary geographic strengths, balancing revenue between the USA and EMEA.

• Combined entity will have over EUR 250 million in sales and EUR 48 million EBITDA (2025 illustrative figures).

Financial terms and conditions

• Enterprise value of EUR 290 million; equity value EUR 250 million, with EUR 194.3 million in cash, EUR 55.7 million in new shares, and EUR 17 million vendor loan.

• 22.3% of purchase price paid in new shares at EUR 22.4/share (14% premium); 77.7% in cash.

• Financing includes EUR 130 million term loan, EUR 80 million bridge to equity, and EUR 10 million revolving credit.

• Rights issue of EUR 80 million fully underwritten by Nordea, to be completed post-closing.

• Sellers receive about 8.5% of shares post-transaction and remain invested in the combined group.

Synergies and expected cost savings

• Targeting over EUR 20 million EBITDA synergies by end of 2029, with 70% realized by end of 2027.

• Synergies mainly from channel optimization, cross-selling, procurement, assembly, supply chain, and SG&A efficiencies.

• Major savings from IT integration, joint purchasing, and supply chain management.

• Integration costs estimated at EUR 20 million, with majority incurred in 2026-2027 and 30% capitalized (mainly IT-related).